Crossmark

Is insulin-like growth factor 1 (IGF-1) system an attractive target inflammatory bowel diseases? Benefits and limitation of potential therapy

Crossref DOI link: https://doi.org/10.1016/j.pharep.2016.03.006

Published Print: 2016-08

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Zatorski, Hubert

Marynowski, Mateusz

Fichna, Jakub
Funding

Funding for this research was provided by:

Medical University of Lodz (503/1-156-04/503-01)

National Science Center (UMO-2013/11/B/NZ7/01301, UMO-2014/13/B/NZ4/01179)

Diamentowy Grant Program of the Polish Ministry of Science and Higher Education (0202/DIA/2015/44)
License Information

Text and Data Mining valid from 2016-08-01
More Information

This article is maintained by: Elsevier

Article Title: Is insulin-like growth factor 1 (IGF-1) system an attractive target inflammatory bowel diseases? Benefits and limitation of potential therapy

Journal Title: Pharmacological Reports

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.pharep.2016.03.006

Content Type: article

Copyright: © 2016 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.